December 7, 2023
Kedrion announces an eight-year extension of the distribution agreement with Kamada in the US for KEDRAB®
July 19, 2023
Kedrion confirms its commitment against Rabies infections in the US
June 2, 2021
Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children
February 10, 2021
Rabies Treatment Demonstrated as Safe and Effective for Use in Children in First Pediatric Trial
August 19, 2020
Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Study Met Its Primary Objective